Clinical trial
Vaccine Treatment for Hormone Refractory Prostate Cancer
NCT00105053 · NewLink Genetics Corporation, Industry · Completed
Key facts
| NCT number | NCT00105053 |
|---|---|
| Title | Vaccine Treatment for Hormone Refractory Prostate Cancer |
| Official title | A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | NewLink Genetics Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | HyperAcute-Prostate Cancer Vaccine |
| Enrollment | 8 |
| Start date | Mar 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Mar 4, 2005 |
| Last update posted | May 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: